Paper35644166
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Danese S and 22 others. Lancet, 2022. Cited by 568 papers, by iCite.
Cite this record
ConductScience Library. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Papers, record 35644166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35644166
- Disease
- ulcerative colitis241 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
- PubMed
- Publication types
- Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acne Vulgaris | Major topic |
| Colitis, Ulcerative | Major topic |
| Nasopharyngitis | Major topic |
| Creatine Kinase | |
| Double-Blind Method | |
| Heterocyclic Compounds, 3-Ring | |
| Humans | |
| Severity of Illness Index | |
| Treatment Outcome |
Source PubMed
Trials4
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02819635 | A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03653026 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT06780683 | Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease | Results | ClinicalTrials.gov | |
| NCT07442045 | Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis | Background | ClinicalTrials.gov |
Comments and corrections4
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 35988576 | Department of Error. | https://conductscience.org/library/papers/35988576 | PubMed |
| Comment in | 35644164 | Upadacitinib for ulcerative colitis. | https://conductscience.org/library/papers/35644164 | PubMed |
| Comment in | 35850194 | Upadacitinib: The New Jak Inhibitor in Town. | https://conductscience.org/library/papers/35850194 | PubMed |
| Comment in | 36191310 | In active UC, upadacitinib induced and maintained remission. | https://conductscience.org/library/papers/36191310 | PubMed |
Cited by368
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 568 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42979323 | Real-world success of de-escalating upadacitinib induction dosing in ulcerative colitis is predicted by steroid-free clinical and biochemical remission, not induction duration. | Crohns Colitis 360 | 2026 | https://conductscience.org/library/papers/42979323 | PubMed |
| 42976274 | Longitudinal timepoint assessment of patient-reported clinical disease activity in ulcerative colitis and Crohn's disease: suitability of a rapid Patient-Reported Outcome 2 (PRO-2) assessment. | J Crohns Colitis | 2026 | https://conductscience.org/library/papers/42976274 | PubMed |
| 42952524 | Benefit-risk profiling of advanced therapies in moderate-to-severe ulcerative colitis: a clustered network meta-analysis. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42952524 | PubMed |
| 42941186 | Inflammatory Bowel Disease: From Multifactorial and Metabolic Pathogenesis to Systemic Disease and Precision Medicine. | Metabolites | 2026 | https://conductscience.org/library/papers/42941186 | PubMed |
| 42928006 | [KASID Guidelines for the Medical Treatment of Ulcerative Colitis: 2026]. | Korean J Gastroenterol | 2026 | https://conductscience.org/library/papers/42928006 | PubMed |
| 42923801 | Chinese expert consensus on the treatment of immune‑mediated inflammatory diseases with Janus kinase inhibitors. | Rheumatol Immunol Res | 2026 | https://conductscience.org/library/papers/42923801 | PubMed |
| 42918627 | Review: optimizing rescue therapy in acute severe ulcerative colitis using infliximab pharmacokinetics-a practical guide for clinicians. | J Crohns Colitis | 2026 | https://conductscience.org/library/papers/42918627 | PubMed |
| 42910148 | Paradoxical Massive Colonic Bleeding during Early Response to Upadacitinib in Acute Severe Ulcerative Colitis: A 3-Case Series. | Inflamm Intest Dis | 2026 | https://conductscience.org/library/papers/42910148 | PubMed |
| 42909122 | Biologic and small-molecule therapies for inflammatory bowel disease: mechanisms, comparative evidence and the emerging pipeline. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42909122 | PubMed |
| 42871137 | Stratified by baseline corticosteroid use: which advanced therapy works best for whom in ulcerative colitis? | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42871137 | PubMed |
| 42865982 | Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidance. | JPGN Rep | 2026 | https://conductscience.org/library/papers/42865982 | PubMed |
| 42846532 | Integrative Transcriptomic and Genetic Analysis Prioritizes IRF1 as a Candidate Regulatory Gene Associated with Ulcerative Colitis. | J Inflamm Res | 2026 | https://conductscience.org/library/papers/42846532 | PubMed |
| 42813045 | From intestinal immune niches to systemic inflammation: programming cellular plasticity and immune redistribution across organs. | Front Immunol | 2026 | https://conductscience.org/library/papers/42813045 | PubMed |
| 42812453 | EPS deficiency aggravates intestinal mucosal inflammation and dysbiosis through disrupting macrophage polarization balance in ulcerative colitis. | Front Immunol | 2026 | https://conductscience.org/library/papers/42812453 | PubMed |
| 42812279 | Korean College of Rheumatology treatment recommendations for patients with axial spondyloarthritis: 2026 update. | J Rheum Dis | 2026 | https://conductscience.org/library/papers/42812279 | PubMed |
| 42798690 | Bridging the Treatment Access Gap: Janus Kinase Inhibitors as First-line Advanced Therapy for Inflammatory Bowel Disease in Resource-variable Settings. | Euroasian J Hepatogastroenterol | 2026 | https://conductscience.org/library/papers/42798690 | PubMed |
| 42781251 | Herpes zoster vaccination in inflammatory bowel disease: Evidence, guidelines, and reality. | World J Virol | 2026 | https://conductscience.org/library/papers/42781251 | PubMed |
| 42772941 | Optimising clinical trial design choices in inflammatory bowel disease. | BMJ Open Gastroenterol | 2026 | https://conductscience.org/library/papers/42772941 | PubMed |
| 42756780 | Dose-Escalated Upadacitinib for Refractory Myositis in Anti-Jo-1-Positive Antisynthetase Syndrome: A Case Report. | Case Rep Rheumatol | 2026 | https://conductscience.org/library/papers/42756780 | PubMed |
| 42739758 | Targeted Therapies in Inflammatory Bowel Disease: Mechanisms, Comparative Evidence, and Clinical Translation. | J Clin Med | 2026 | https://conductscience.org/library/papers/42739758 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| JAK1 | 3716 | PubTator's text mining | https://conductscience.org/library/genes/3716 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| UPADACITINIB | CHEMBL3622821 | Results | 3 | https://conductscience.org/library/drugs/CHEMBL3622821 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35644166
GET https://conductscience.org/api/papers/v1/35644166/authors?page=2